The effect of different dose of heparin using in peripheral arteriovenous synchronous blood exchange transfusion for neonatal hyperbilirubinemia
Effect of Heparin Dose in Neonatal Hyperbilirubinemia Treatment
Sažetak
Background: To explore the optimal dosage of heparin in peripheral arteriovenous automatic synchronous exchange transfusion therapy for neonatal hyperbilirubinemia.
Methods: A total of 185 neonates received peripheral arteriovenous synchronous blood exchange transfusion for hyperbilirubinemia were enrolled from pediatric department of the Ganzhou People's Hospital between January 2018 and June 2020, which were randomly divided into four groups. On the basis of exchange transfusion, different dose of heparin was pumping at the bleeding site of artery (A: no heparin; B: 100 U/h heparin; C: 200 U/h heparin; D: 300 U/h heparin). The indexes of exchange transfusion efficacy, including total bilirubin conversion rate, indirect bilirubin conversion rate, hemoglobin concentration, the platelet number and APTT value was measured before and after therapy. The sites of artery puncture, the sites and rate of vascular occlusion were counted and analyzed.
Results: There was no significant difference for total bilirubin conversion rate, indirect bilirubin conversion rate, hemoglobin concentration platelet number and APTT value before and after exchange transfusion between the four groups (P >0.05). In addition, there was no statistical significance in artery puncture sites between the four groups (P > 0.05). Significant difference in total rate of vascular occlusion and rate of radial artery occlusion were found between the four groups (P< 0.05).
Conclusion: Different dose of heparin using in peripheral arteriovenous synchronous blood exchange transfusion did not affect the therapeutic effect or coagulation function of patients, but could reduce the rate of occlusion depending by the site of arterial puncture.
Reference
1. Yu B, Hu F. Exploration of the pathogenic factors of neonatal jaundice and the clinical effect of blue phototherapy. Am J Transl Res 2021; 13(6): 6802-6.
2. Olusanya BO, Kaplan M, Hansen T. Neonatal hyperbilirubinaemia: a global perspective. Lancet Child Adolesc 2018; 2(8): 610-20.
3. Boskabadi H, Rakhshanizadeh F, Zakerihamidi M. Evaluation of Maternal Risk Factors in Neonatal Hyperbilirubinemia. Arch Iran Med 2020; 23(2): 128-40.
4. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics 1992; 89(5 Pt 1): 809-18.
5. Lucey JF. The future demise of exchange transfusions for neonatal hyperbilirubinemia. Dev Med Child Neurol 1968; 10(4): 521-2.
6. Patra K, Storfer-Isser A, Siner B, Moore J, Hack M. Adverse events associated with neonatal exchange transfusion in the 1990s. J Pediatr-Us 2004; 144(5): 626-31.
7. Murki S, Kumar P. Blood exchange transfusion for infants with severe neonatal hyperbilirubinemia. Semin Perinatol 2011; 35(3): 175-84.
8. Bujandric N, Grujic J. Exchange Transfusion for Severe Neonatal Hyperbilirubinemia: 17 Years' Experience from Vojvodina, Serbia. Indian J Hematol Blo 2016; 32(2): 208-14.
9. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 1998; 20(2): 156-67.
10. Bolten SN, Rinas U, Scheper T. Heparin: role in protein purification and substitution with animal-component free material. Appl Microbiol Biot 2018; 102(20): 8647-60.
11. Hovi L, Siimes MA. Exchange transfusion with fresh heparinized blood is a safe procedure. Experiences from 1 069 newborns. Acta Paediatr Scand 1985; 74(3): 360-5.
12. VALENTINE GH. Exchange transfusion in the newborn using heparinized blood. Can Med Assoc J 1958; 78(12): 927-31.
13. PEW WL. Exchange transfusion using heparinized blood. J Pediatr-Us 1956; 49(5): 570-3.
14. Samsom JF, Groenendijk MG, van der Lei J, Okken A. Exchange transfusion in the neonate, a comparison between citrate-, heparinized- and reconstituted whole blood. Eur J Haematol 1991; 47(2): 153-4.
15. Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. Am Fam Physician 2014; 89(11): 873-8.
16. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. Brit J Hosp Med 2017; 78(12): 699-704.
17. Owen HG, Brecher ME. Partial colloid starch replacement for therapeutic plasma exchange. J Clin Apheresis 1997; 12(2): 87-92.
18. Watchko JF. Hyperbilirubinemia in African American neonates: clinical issues and current challenges. Semin Fetal Neonat M 2010; 15(3): 176-82.
19. Brodersen R, Stern L. Deposition of bilirubin acid in the central nervous system--a hypothesis for the development of kernicterus. Acta Paediatr Scand 1990; 79(1): 12-9.
20. Watchko JF. Route of exchange transfusion in neonates with hyperbilirubinemia. Pediatr Crit Care Me 2011; 12(1): 110-1.
21. Ji Y. Fully automated simultaneous peripheral arteriovenous exchange transfusion not seen to aggravate brain function and the disorder of the internal environment in neonates with severe hyperbilirubinemia. Pediatr Neonatol 2021; 62(6): 687-8.
22. Aslani S, Kabiri M, HosseinZadeh S, Hanaee-Ahvaz H, Taherzadeh ES, Soleimani M. The applications of heparin in vascular tissue engineering. Microvasc Res 2020; 131: 104027.
23. Schindler E, Kowald B, Suess H, Niehaus-Borquez B, Tausch B, Brecher A. Catheterization of the radial or brachial artery in neonates and infants. Pediatr Anesth 2005; 15(8): 677-82.
24. Gray E, Hogwood J, Mulloy B. The anticoagulant and antithrombotic mechanisms of heparin. Handb Exp Pharmacol 2012; (207): 43-61.
25. Beurskens D, Huckriede JP, Schrijver R, Hemker HC, Reutelingsperger CP, Nicolaes G. The Anticoagulant and Nonanticoagulant Properties of Heparin. Thromb Haemostasis 2020; 120(10): 1371-83.
Sva prava zadržana (c) 2023 Xueyun Guan, Jing Guo, Dongsu Xiao, Zhong Wu
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.